ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
27.44
+0.89 (3.35%)
At close: Dec 5, 2025, 4:00 PM EST
27.60
+0.16 (0.58%)
After-hours: Dec 5, 2025, 7:59 PM EST
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for ACADIA Pharmaceuticals stock have an average target of 29.24, with a low estimate of 17 and a high estimate of 39. The average target predicts an increase of 6.56% from the current stock price of 27.44.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACADIA Pharmaceuticals stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Buy | 7 | 8 | 8 | 8 | 8 | 8 |
| Hold | 7 | 7 | 7 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Total | 18 | 20 | 21 | 21 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Hold Maintains $24 → $29 | Hold | Maintains | $24 → $29 | +5.69% | Dec 2, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $33 → $31 | Buy | Maintains | $33 → $31 | +12.97% | Nov 17, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $34 → $32 | Buy | Maintains | $34 → $32 | +16.62% | Nov 6, 2025 |
| Needham | Needham | Strong Buy Maintains $28 → $29 | Strong Buy | Maintains | $28 → $29 | +5.69% | Nov 6, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +20.26% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
1.10B
from 957.80M
Increased by 15.16%
Revenue Next Year
1.23B
from 1.10B
Increased by 11.42%
EPS This Year
0.83
from 1.36
Decreased by -38.73%
EPS Next Year
0.82
from 0.83
Decreased by -1.91%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.4B | ||||
| Avg | 1.1B | 1.2B | ||||
| Low | 1.1B | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 19.2% | 25.4% | ||||
| Avg | 15.2% | 11.4% | ||||
| Low | 9.7% | 2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.03 | 1.25 | ||||
| Avg | 0.83 | 0.82 | ||||
| Low | 0.54 | 0.40 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -24.3% | 50.0% | ||||
| Avg | -38.7% | -1.9% | ||||
| Low | -60.4% | -52.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.